Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

DECEMBER 18, 2019

Notably, the increase comes after the company recently broke into the European pharma-market after getting green-lighted from the Irish Government to sell its phytocannabinoid-derived “CannEpil” product to epilepsy sufferers. Both products are proprietary medicinal drugs developed internally through MGC’s research and development divisions.

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

Cannabis Law Report

SEPTEMBER 6, 2021

The steadily aging population across the globe has played a significant role in driving the demand for medical cannabis as geriatric patients are more likely to develop chronic illnesses and require more physician visits. 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications.

Chronic Pain 86

Chronic Pain Research and Development Clinical Trials Epilepsy 86

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

SEPTEMBER 22, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times. A vast majority of CBD developers are pursuing compounds targeted to CB2 that have minimal CB1 affinity.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman Bio.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

MARCH 2, 2020

The move follows the law change in October 2018 to allow specialist doctors to prescribe cannabis-based products for medicinal use where clinically appropriate in the UK, which has been condemned within the UK’s cannabis sector. By October 29, less than five patients had successfully obtained medicinal cannabis.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

The Cannigma

JUNE 15, 2021

Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-? About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

CannaMD

AUGUST 8, 2020

Researchers believe cannabis contains over 100 unique chemical compounds! government classified all cannabis varieties, including hemp, as Schedule I under the Controlled Substances Act (despite decades of agricultural research detailing its differences from marijuana). What makes CBD special? In 1970, the U.S. CBD & Epidiolex.

CBD 99

CBD DEA Research and Development Hemp 99

MMJ Recs

DECEMBER 22, 2023

Historically, marijuana was vilified and classified as a Schedule I controlled substance, which hindered both research and public acceptance. One of the key drivers of this shift is the increasing body of scientific research highlighting the medical properties of cannabinoids, the active compounds in marijuana.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

Medical marijuana laws have changed dramatically across the country in recent years, and now cannabis pharmaceuticals appear to be the next big leap forward in cannabis law reform. The recent years have seen drastic marijuana law changes in several states. Cannabis Legalization Throughout The Country. Dravet Syndrome.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Cannabis Law Report

DECEMBER 28, 2021

The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., Moreover, the FDA has also allowed researchers to conduct CBD trials. But things have changed after FDA eased out regulations in 2015 to carry out CBD trials.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

Cannabis Law Report

JULY 13, 2019

clinical trials have been made by Members of Parliament. But it says one of the barriers to research is that industry is not always prepared to supply products for research trials. Instead, it would be helpful to encourage these companies to develop a greater understanding in the UK.”. CBD Testers.co

Research and Development 40

Research and Development Clinical Trials Epilepsy Patients 40

Cannabis Law Report

NOVEMBER 24, 2019

Recommendations for research. Severe treatment-resistant epilepsy. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy. potential impact on structural and functional brain development. Recommendations. Rationale and impact.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

APRIL 10, 2019

In November, UK law changed to allow clinicians to prescribe medical cannabis under limited conditions. The Government need to push for centres of excellence to help to stimulate the research they say they are calling for.”. Here’s a quick precis care of Cannabis Wire Daily Newswire. We are working hard to get the right approach.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

NOVEMBER 29, 2019

For instance, THC has shown the potential to help in the treatment of conditions like PTSD, depression, eating disorders, and epilepsy. Preliminary research has also shown that CBD has the potential to help patients with Parkinson’s and Alzheimer’s diseases. That’s why some people choose THC oil. THC Oil Benefits. THC Oil Effects.

Oil 104

Oil THC Cannabinoids Research and Development 104

Cannabis Law Report

FEBRUARY 3, 2022

CBD oils have various health benefits in treating medical disorders like epilepsy, anxiety, cancer, acne, diabetes, and others. Product Development Via Research and Novel Product Delivery Solutions. Researchers Are Studying New Uses of Medical Marijuana. Clinical Trials of Cannabis Are Still on Going.

Indica 52

Indica Oil Legalization Research and Development 52

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

Cannabis Law Report

JULY 15, 2019

PUBLISHER: CANNABIS LAW REPORT. July 18 marks the first anniversary of the Portuguese medical cannabis law. As we wrote one year ago , this law showed some inconsistencies due to political setbacks and last minute amendments, which could harm its success. João Taborda da Gama. Joana Albernaz Delgado.

Medicine 40

Medicine Clinical Trials Patients Access 40

Cannabis Law Report

DECEMBER 7, 2021

Adverse mental events were reported as well, however, more research should be performed to assess well this outcome. This trend is also observed in the pediatric population, where MCs are authorized in children for refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome 2. Introduction. Adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 1, 2021

Drake is well-known as an inspiring and inclusive leader who is dedicated to the development of her teams and solely focused on organizational success for the benefit of patients. Company remains on track for potential approval of Vicineum™ in the US in August 2021. CAMBRIDGE, Mass.–(BUSINESS

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

SEPTEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. Mack, Chairman and CEO of Virpax.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We This product candidate is being funded through a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS).

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

– Multiple Contracts Awarded to Support the Development and Manufacturing of Envelta (NES100) – BERWYN, Pa.–(BUSINESS IND-enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement (CRADA) with NCATS entered into by Virpax in August of 2020. “We

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. Food and Drug Administration (“FDA”). Forward-Looking Statement.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

DECEMBER 23, 2021

Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. However, regulations are constantly shifting.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Cannabis Law Report

JANUARY 26, 2022

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

OCTOBER 26, 2019

ii Non-clinical studiesAlthough the use of animals in research is separately regulated by each state and territory, all require compliance with the Australian Code for the Care and Use of Animals for Scientific Purposes (Animal Code). One such circumstance is a clinical trial. medical practitioner), an organisation (e.g.,

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

DECEMBER 28, 2021

These accomplishments include accelerated development of our existing product candidates, broadening our pipeline of product candidates, and utilizing grants where appropriate. We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 1, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, today announced that Chairman and CEO Anthony P. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 1, 2019

In the months that followed, Fitzsimons and Yeend publicly criticised the government for failing to facilitate their plans quickly enough; the government ruled the Holden plant out as a potential site for cannabis cultivation; Australian Cannabis Corporation lost a major research partnership; and the pair had a messy, public falling out.

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

SMPL

MAY 26, 2020

For years, he’d been determined to connect the nascent CBD research he heard about at symposiums abroad with the medical marijuana movement in California. This makes further research very difficult to do, and causes sick people in many states to be treated as criminals. San Francisco weekly. We were in communication for many years.”.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40